Article
Clinical performance and utility of a noninvasive urine-based methylation biomarker—TWIST1/Vimentin to detect urothelial carcinoma of the bladder
2023-11-06
Abstract excerpt
Traditional clinical modalities for diagnosing bladder urothelial carcinoma (BUC) remain limited due to their invasive nature, significant costs, discomfort associated with cystoscopy, and low sensitivity to urine cytology. Therefore, there is an urgent need to identify highly sensitive, specific, and noninvasive biomarkers for the early detection of this neoplasm. Hypermethylated TWIST 1 /Vimentin promoter may be...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- f9bc58e9-b373-50ff-8f1f-88e09898bb8e
- DOI
- 10.21203/rs.3.rs-3526502/v1
